Scientists finally uncover why promising cancer drugs keep failing

Scientists have identified why BET inhibitors, a class of cancer drugs, have failed in clinical trials. The research shows BRD2 and BRD4 proteins have distinct roles in gene activation, with BRD2 acting as a 'stage manager' and BRD4 triggering gene activation. Blocking both proteins simultaneously disrupts the process, leading to inconsistent drug effectiveness.